136 results about "Tuberculoma" patented technology

The invention discloses an electrochemical biosensor for detecting mycobacterium tuberculosis. The sensor takes a porous membrane as a base material, the inner wall of a pore channel of the porous membrane is co-modified with a polydopamine (PDA) and conductive carbon material composite layer, and an amino-modified specific capture probe based on a mycobacterium tuberculosis ESAT-6 gene is fixed on a modification layer through covalent binding. When a target gene is captured by a probe, the volume effect of the target gene causes blockage of a porous channel of the porous membrane, so that electrochemical signals (such as current) of the sensor are changed, and high-sensitivity and specific detection of mycobacterium tuberculosis is realized. According to the invention, a porous structure, biological probe specific fixation and an electrochemical signal conversion technology are combined, and a novel efficient tool is provided for rapid diagnosis of tuberculosis.

The invention discloses a method for establishing indirect ELISA (enzyme-linked immunosorbent assay) for detecting mycobacterium bovis Lprl, which comprises the following steps: preparing mycobacterium bovis Lprl protein, taking the purified protein as an antigen, and determining conditions such as optimal antigen coating concentration, serum dilution, serum incubation time, secondary antibody dilution concentration, incubation time and the like. The established indirect ELISA detection method does not have cross reaction with other bovine pathogens, the specificity is good, the detection accuracy is high, and the total coincidence rate of test results of intradermal allergy with bovine tubercle bacillus is 95.8%; the intra-batch variation coefficient of the detected samples is 2.43%-3.61%, the inter-batch variation coefficient is 2.83%-3.96%, and the intra-batch variation coefficient and the inter-batch variation coefficient are both smaller than 10%. A new diagnosis target is developed, the established indirect ELISA method has the characteristics of high sensitivity, strong specificity, good repeatability and the like, the operation is easy, and a new method is provided for the detection work of the mycobacterium bovis.

This invention provides a data storage method and system for tuberculosis detection, relating to the field of tuberculosis detection technology. The data storage method for tuberculosis detection includes the following steps: S1. Collecting whole-genome sequencing data of Mycobacterium tuberculosis, host serum IgG titer, and drug sensitivity test results; S2. Calculating genetic distance D based on a reverse evolution model to generate four-dimensional spatiotemporal coordinates (t, x, y); S3. Performing data partitioning and storage based on the drug target barrier value β; S4. Generating dynamic metadata using a host-pathogen dynamics model and compressing and storing it. This invention implements a dynamic storage entropy adjustment algorithm at the hardware and software collaborative level, continuously optimizing the matching efficiency of data compression and physical storage. This results in an intelligent data hub that can perceive the evolutionary pulse of pathogens and autonomously optimize resources, providing support for clinical tuberculosis prevention and control decisions with temporal depth, spatial correlation, and risk evolution.

To provide methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle.SOLUTION: The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The method provided herein results in a change from the baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.SELECTED DRAWING: None

The invention discloses a detection system and method for identifying mycobacteria and drug resistance genes of the mycobacteria based on nanopore sequencing, and relates to the field of biological medicine, the detection system comprises a specific targeted enrichment module, a nanopore sequencing module and a biological information analysis module; the specific targeted enrichment module comprises a probe combination, and the probe combination covers a mycobacterium tuberculosis complex conservative identification gene, species-specific genes of common nontuberculous mycobacteria and mycobacterium leprosy, and full-length or partial sequences of drug resistance related genes in a targeted manner; by utilizing the characteristics of nanopore length reading length and real-time sequencing and a tuberculosis specific targeted enrichment strategy, accurate identification of a mycobacterium tuberculosis complex group, synchronous typing of 42 mycobacteria, analysis of 24 drug-resistant genes, and efficient detection of structural variation and low-abundance heterogeneity drug-resistant mutation are realized, the detection period is shortened, the detection cost is reduced, and the detection efficiency is improved. And a comprehensive and reliable technical basis is provided for accurate diagnosis and treatment of mycobacterium infection.

The present application relates to the technical field of diagnostic markers, in particular to a marker combination and its application in diagnosing active tuberculosis and distinguishing between latent tuberculosis infection and active tuberculosis. The lectin combination provided by the present application can be used as a marker for ATB diagnosis and distinguishing between LTBI and ATB, and has high specificity and sensitivity. The lectin combination provided by the present application in combination with detection of specific antibodies of mycobacterium tuberculosis antigens can further improve the diagnostic effect. The marker and its detection products provided by the present application have good application potential in ATB diagnosis and distinguishing between LTBI and ATB, and are expected to overcome the limitations of existing diagnostic techniques, improve the diagnostic accuracy and sensitivity of tuberculosis, and provide new ideas and technical means for early detection, precise treatment and effective prevention and control of tuberculosis.

The invention relates to a mycobacterium tuberculosis EspB polyclonal antibody as well as a preparation method and application thereof. The purified EspB antibody has good detection specificity, only reacts with mycobacteria, and does not react with other common pneumonia pathogenic bacteria. The EspB polyclonal antibody specifically recognizes mycobacteria EspB, comprises mycobacterium tuberculosis and nontuberculous mycobacteria (NTM) EspB which grows slowly and rapidly, and can be used for detecting tuberculosis and NTM diseases.

To provide monoclonal antibodies specific to epitopes found within lipoarabinomannan (LAM) and phosphatidyl-myo-inositol mannoside 6 (PIM6) for the diagnosis and treatment of Mycobacterium tuberculosis infections.SOLUTION: The present invention provides a monoclonal anti-PIM6 / LAM antibody, or an antigen-binding portion thereof, that specifically binds to an epitope present in LAM and PIM6, the epitope including at least one polymannose structure. The anti-PIM6 / LAM antibody includes CDR1 light chain variable region, CDR2 light chain variable region, CDR3 light chain variable region, CDR1 heavy chain variable region, CDR2 heavy chain variable region, and CDR3 heavy chain variable region, each including a specific amino acid sequence.SELECTED DRAWING: Figure 1

The invention relates to a spinal infection and tuberculosis intelligent diagnosis method based on an image large model, the core idea of the method is pre-training of a base and hierarchical fine tuning, that is, firstly, a general spinal image visual large model is trained based on a DINOv2 algorithm by using mass unmarked spinal MRI data, so that the spinal image visual large model masters the anatomical structure and basic pathological characteristics of the spinal column; and then a two-stage cascaded diagnosis network is designed on the base, so that the problems of whether infection exists or not and the infection type are solved respectively. The problems that in spinal infection differential diagnosis, labeling data is deficient and the feature extraction capacity is insufficient are solved, a DINOv2 self-supervised pre-training technology is utilized to construct a visual feature base model, automatic screening of spinal infectious diseases and accurate differential diagnosis of infection subtypes are achieved through a hierarchical two-stage reasoning architecture, and the accuracy of the spinal infection differential diagnosis is improved. Dependence on annotation data is greatly reduced, and identification accuracy of difficult cases is remarkably improved.

The invention discloses a nanometer antibody of mycobacterium tuberculosis early secretory protein ESAT-6 and application thereof, relates to the technical field of antibody recombination and genetic engineering antibodies, and is characterized by providing two nanometer antibodies AEN1 and AEN5 which are derived from a total synthesis alpaca nanometer antibody yeast display library and are combined with ESAT-6 in high affinity, DNA sequences for coding the AEN1 and the AEN5, a carrier containing the DNA, a carrier containing the carrier containing the DNA, and a carrier containing the carrier containing the carrier containing the DNA. The invention relates to a vector, a host cell containing the vector, and a method for preparing AEN1 and AEN5 by utilizing genetic engineering. And the method for quantitatively detecting the ESAT-6 by using the double-antibody sandwich ELISA is established. Detection on clinical specimens of tuberculosis shows that the sensitivity of the diagnosis method is 94.9%, and the specificity is 100%. The antibody is used for preparing gold-labeled rapid test paper, and the ESAT-6 can be rapidly detected from serum of a mycobacterium tuberculosis infected patient.

The application discloses a kind of non-tuberculous mycobacterial lung disease and pulmonary tuberculosis CT image classification method, mainly including the following steps: image feature map is extracted by encoder and image feature map is divided into multiple examples, each example represents the feature information in certain area of image;The correlation weight of example and classification task is calculated, and the example is aggregated into bag feature representation according to the weight to express the characteristics of CT image;Bag feature representation is predicted as CT image category by classifier;According to the correlation weight, important examples are selected, and are evaluated by classifier, to express the correlation degree of the learning content and expected content of network;Loss function is constructed, including bag classification loss and correlation loss, respectively representing the difference between CT predicted value and true value and the difference between model learning content and expected content.The method can realize the binary classification of non-tuberculous mycobacterial lung disease and pulmonary tuberculosis CT image, and is superior to the classification accuracy of existing method.

The present invention is directed to a vaccine composition against a disease caused by Mycobacterium tuberculosis, said composition comprising at least four nucleic acids selected from the following groups: a. a nucleic acid encoding an Ag85A, Ag85B, or Ag85C antigen; b. a nucleic acid encoding a resuscitation promoting factor (Rpf) selected from the group consisting of: RpfA, RpfB, RpfC, RpfD and RpfE; c. a nucleic acid encoding a PE / PPE antigen selected from the group consisting of: PE5, PE13, PE15, PE29, PE31, PPE1, PPE2, PPE18, PPE20, and PPE68; d. a nucleic acid encoding a disease-reactivation-related antigen selected from the group consisting of: Rv1234 / MMAR_4207, and Rv0359 / MMAR_0678, wherein said vaccine composition comprises at least one nucleic acid from each of group a, b, and c; and wherein the nucleic acids are provided on one or more nucleic acids constructs.

This invention provides a chemotherapy catheter for spinal tuberculosis, comprising a catheter with a drug channel, a flexible tube at the front end of the catheter with multiple through holes communicating with the drug channel, and a built-in one-way structure. The one-way structure includes an elastic rubber sheet at one end fixed to the inner wall of the drug channel; multiple elastic rubber sheets are stacked together in a conical shape; and a connector is connected to the rear end of the catheter, with a drug injection end for injecting medication. This invention, by inserting the catheter into the patient's body, injects medication through the drug injection end, which then passes through the drug channel and the one-way structure to prevent backflow, and finally flows out through the multiple through holes, thereby widely dispersing the medication and improving drug utilization.

The application provides a primer probe set and a kit for detecting a rifampicin-resistant gene of Mycobacterium tuberculosis, and belongs to the technical field of molecular biology detection.The primer probe set comprises RAA primers and qPCR primers targeting the rpoB gene, probe primers targeting the wild-type rpoB gene, and probe primers targeting the mutant rpoB gene.The application adopts the detection methods of RT-RAA and qPCR in sequence, and the above specific primer probe set can be combined to simultaneously and rapidly detect the 516, 526, 531 and 533 sites of the rpoB gene of Mycobacterium tuberculosis, has good specificity, and the detection sensitivity can reach 5 copies / ul, is 20 times higher than the sensitivity of qPCR (100 copies / ul), and has a 5% detection capability for heterogenic drug resistance mutation; the detection method can also greatly shorten the detection time.

The invention relates to the technical field of biology, in particular to a protective monoclonal antibody targeting Mycobacterium tuberculosis PspA and a preparation method and application thereof, the protective monoclonal antibody comprises at least one of the following CDR sequences or a sequence with one amino acid substituted, deleted or increased: a heavy chain variable region CDR sequence: SEQ ID NO: 4-6; the light chain variable region CDR sequences are as shown in SEQ ID NO: 8-9 and WAS. The antibody or the antigen binding fragment can specifically bind to PspA protein of mycobacterium tuberculosis (MTB), shows efficient antituberculous activity in vivo and in vitro, specifically, can significantly enhance phagocytosis of macrophages on tubercle bacillus, inhibit tubercle bacillus growth and the like, and is clear in sequence and structure, so that the antibody or the antigen binding fragment is easy to develop and transform, and has broad application prospects. And moreover, an immune-mediated treatment mechanism is not easy to induce pathogens to generate drug resistance, so that when being applied to prevention and treatment of tuberculosis, not only is a new choice provided for treatment of tuberculosis, but also an important basis is provided for response of drug-resistant strains, development of diagnostic reagents, vaccine development and the like, and the application prospect is wide.

The application discloses a kind of absolute quantitative detection method of child respiratory tract multi-pathogen based on multi-target ladder microarray and exogenous internal reference correction.The method sets up independent micro-reaction unit to different pathogen, adds fixed amount of exogenous internal reference nucleic acid, and calculates template number by positive unit proportion combined with Poisson distribution model, then corrects the result by using the theoretical addition amount of exogenous internal reference, so as to realize parallel detection and absolute quantification of pathogen such as bocavirus, adenovirus, mycobacterium tuberculosis and mycoplasma pneumoniae without standard curve and special digital PCR equipment.The application has the advantages of high sensitivity, strong anti-interference ability, suitable for mixed infection sample analysis and clinical application, etc.

Provided herein are method of treating a patient with nontuberculous mycobacteria by administering nitric oxide to the patient for at least 100 days to increase functional capacity and quality of life of the patient.

In one aspect, the disclosure relates to compounds effective in the treatment of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis as well as drug-sensitive tuberculosis, methods of making the same, pharmaceutical compositions comprising the same, and methods of treating bacterial infections caused by Mycobacterium tuberculosis using the same. In an aspect, the compounds and pharmaceutical compositions are not cytotoxic. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

A human antibody comprising an antigen binding domain which binds PstS1 of Mycobacterium tuberculosis (TB) for use in preventing or treating TB infection in a subject in need thereof is provided. Also provided are vaccine compositions and conjugates of such antibodies.

The present application relates to a kind of mycobacterium tuberculosis protective antigen combination and its application, specifically, the antigen of the application is combination antigen, at least includes the following antigen: Ag85B, Rv2465c, Rv2029c, Rv3406;The application is the vaccine for resisting mycobacterium tuberculosis.

The invention relates to the technical field of auxiliary diagnosis of tuberculosis patients, in particular to a sampling device convenient for tuberculosis patients to use, which comprises a sputum cup, a sliding groove is arranged at the top end of the sputum cup along the periphery of the sputum cup, a pressing component is in sliding fit in the sliding groove, and a plurality of springs are arranged in the sliding groove; the top of the pressing assembly is fixedly connected with a protection assembly for surrounding the mouth of a patient; the inner bottom of the pressing assembly is fixedly connected with an opening and closing assembly for controlling the protection assembly to communicate with the sputum cup; an air bag ring is arranged on the inner wall of the protection assembly, a plurality of inflation channels are formed in the pressing assembly, and the inflation channels all extend into the protection assembly and communicate with the air bag ring. The pressing assembly drives the opening and closing assembly to be opened, the protection assembly surrounds the mouth, the air bag ring is attached to the skin around the mouth of a patient, droplet diffusion is reduced, the infection risk is reduced, the sampling safety is improved, and diagnosis of the pulmonary tuberculosis patient is assisted.

The present disclosure provides agents and methods for preventing or treating tuberculosis using RNA. The RNA encoding variants of antigens of Mycobacterium tuberculosis ox of fragments thereof is formulated and administered in a way that the variants are produced by cells of a subject, in particular after intramuscular or intravenous administration of the RNA.

This invention discloses miRNA biomarkers for the auxiliary diagnosis of tuberculosis and their applications. This invention claims protection for the use of substances for detecting miRNAs in serum exosomes in the preparation of products; the purpose of said products is for the diagnosis or auxiliary diagnosis of tuberculosis patients or for the diagnosis or auxiliary diagnosis of active pulmonary tuberculosis patients. The miRNAs are any one or any combination of the following five miRNAs: miR-28-3p, miR-193b-5p, miR-370-3p, miR-1246, and miR-2110. This invention also claims protection for the use of substances for detecting serum exosome miRNAs in the preparation of products; the purpose of said products is for the diagnosis or auxiliary diagnosis of latent tuberculosis infection. The miRNAs are any one or any combination of the following three miRNAs: let-7e-5p, let-7d-5p, and miR-140-5p. This invention lays the foundation for further development of rapid early diagnosis techniques and methods for tuberculosis.

This invention discloses a method for predicting the risk of thoracic and lumbar tuberculosis based on lesion feature matching, belonging to the field of tuberculosis risk prediction. The method includes: collecting relevant symptoms of thoracic and lumbar tuberculosis to obtain a symptom set; searching for diseases with corresponding thoracic and lumbar tuberculosis symptoms to obtain a set of associated diseases for each symptom; collecting case sets of thoracic and lumbar tuberculosis and each associated disease, and measuring the distinguishing ability of each thoracic and lumbar tuberculosis symptom to obtain the symptom-specific weight of each symptom; constructing a preliminary tuberculosis risk prediction model based on the symptom-specific weights of each symptom, incorporating the influence of infection probability, symptom matching, and lesion feature matching; collecting case data of the subjects to be tested, and using the preliminary tuberculosis risk prediction model to predict the thoracic and lumbar tuberculosis risk of the subjects. This invention solves the problem that existing methods mostly rely on personal experience and lack macro-level data integration, leading to inaccurate early risk prediction.

The present invention provides novel primers and sloppy molecular beacons and molecular beacon probes for amplifying segments of different genes in MycobacteriumTuberculosis to identify the presence of M. tuberculosis DNA and / or to identify resistance to anti-tuberculosis drugs.SOLUTION: Oligonucleotide sets are provided for amplifying a portion of an M. tuberculosis region selected from the group consisting of rpoB, gyrA, gyrB, inhA promoter, rrs, eis promoter, embB, katG, dosR, IS6110, and IS1081 genes.SELECTED DRAWING: None

The invention provides a double qPCR (quantitative polymerase chain reaction) detection method capable of simultaneously detecting mycobacterium tuberculosis and mycobacterium paratuberculosis. An Rv3876 gene and an IS900 gene are selected as specific targets, a test result shows that the single qPCR detection sensitivity of mycobacterium tuberculosis and mycobacterium paratuberculosis is 1.35 * 10 < 3 > copies / microliter and 1.29 * 10 < 3 > copies / microliter and is improved by 10 times compared with a conventional PCR, a double qPCR detection method is established on the basis, the sensitivity of the double qPCR detection method is equivalent to that of single qPCR, and the specificity is good; in simulation of clinical milk sample detection, a sample boiling method is screened as an optimal method for extracting DNA of two pathogens, high specificity and sensitivity are achieved, interference of inhibitors in fresh milk can be effectively removed, detection stability is ensured, and the method is expected to be a powerful tool for rapid detection of mycobacterium tuberculosis and mycobacterium paratuberculosis in the fresh milk.

The invention discloses a composite water-soluble vaccine adjuvant and a preparation method thereof, and belongs to the technical field of biological medicines. The adjuvant is based on a composite technology of a water-soluble component and a targeted delivery carrier, through a dual targeting effect of mannose modified beta-glucan, the uptake efficiency of dendritic cells on antigens is remarkably improved, and regulation and control on immune response are realized in cooperation with levamisole. The adjuvant has the characteristics of uniform particle size, excellent water solubility, good storage stability and the like, the immunological enhancement effect of the adjuvant is remarkably superior to that of a traditional adjuvant, and the adjuvant can be widely applied to research and development of vaccines for influenza, tuberculosis, tumor and the like, and has important clinical value and industrialization potential.

The application discloses application of elvitegravir in preparation of an inhibitor of mycobacterium tuberculosis or non-tuberculous mycobacteria, and relates to the technical field of biological medicine.The application discloses, for the first time, that elvitegravir has the effect of inhibiting intracellular survival of mycobacterium tuberculosis or non-tuberculous mycobacteria at the level of macrophages, has the effect of anti-tuberculosis at the level of macrophages, and can be applied to preparation of an inhibitor of mycobacterium tuberculosis or non-tuberculous mycobacteria.The application also discloses that the anti-tuberculosis effect of elvitegravir at the level of macrophages is not the direct action of antibiotics on bacteria, but the inhibition of intracellular survival of tubercle bacillus by targeting and regulating host immune response, so that elvitegravir also has the potential of an immunomodulator, can realize the anti-tuberculosis effect by regulating the immune response of the body to tubercle bacillus infection, and is not affected by drug resistance of mycobacterium tuberculosis, and has a good treatment effect on multidrug-resistant tuberculosis.